Salcaprozate sodium

Salcaprozate sodium has been studied in 3 papers since 2026: 1 trial in people, 2 in animals; 3 in the past year. The newest paper, Nov 3, 2026: “Discovery, optimization, and Phase 1 evaluation of a novel, orally available GLP-1R/GIPR dual agonist”.

Intervention

3 papers study it1 more mentions it5 findingsUpdated

PubChem

2 new papers in 30 daysSee all 4 papers on salcaprozate sodium

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country; 2 trials, none about aging.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • 2 trials, none about aging
  • Funder: Hospital Research Foundation
  • Human trial1
  • Animals2

What is salcaprozate sodium linked with?

5

Studies link salcaprozate sodium with 5 measures, among them liver weight, BDNF and TNF-alpha.

Liver weight

upin rats1

1 study
  1. Salcaprozate sodium is associated with liver weight in rats (healthy rats).

    “SNAC-treated animals also exhibited increased liver weight and reduced caecum mass”

    Animalshealthy ratsliver22 mg/kg/day21 days

    Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery

    Journal of controlled release : official journal of the Controlled Release Society

BDNF

downin rats1−85%

1 study
  1. Salcaprozate sodium is associated with BDNF in rats (healthy rats; monotherapy) (−85%).

    “Plasma cytokine analysis showed elevated tumor necrosis factor-α (TNF-α, 70%) and suppressed brain-derived neurotrophic factor (BDNF, 85%)”

    Animalshealthy rats; monotherapy22 mg/kg/day21 days

    Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery

    Journal of controlled release : official journal of the Controlled Release Society

More on BDNF

TNF-alpha

upin rats1+70%

1 study
  1. Salcaprozate sodium is associated with TNF-alpha in rats (healthy rats; monotherapy) (+70%).

    “Plasma cytokine analysis showed elevated tumor necrosis factor-α (TNF-α, 70%) and suppressed brain-derived neurotrophic factor (BDNF, 85%)”

    Animalshealthy rats; monotherapy22 mg/kg/day21 days

    Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery

    Journal of controlled release : official journal of the Controlled Release Society

More on TNF-alpha

Fecal butyrate

downin rats1−77%

1 study
  1. Salcaprozate sodium is associated with fecal butyrate in rats (healthy rats) (−77%).

    “These compositional changes correlated with reduced predicted saccharolytic enzyme abundance and fecal butyrate concentrations (-77% SNAC, -75% SEM-SNAC).”

    Animalshealthy rats22 mg/kg/day21 days

    Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery

    Journal of controlled release : official journal of the Controlled Release Society

More on Fecal butyrate

Gut microbiota composition

mixedin rats1

1 study
  1. Salcaprozate sodium is associated with gut microbiota composition in rats (healthy rats; compared with the control group) (Muribaculaceae −62%; Bacteroidaceae −77%; β-diversity PERMANOVA p < 0.05).

    “SNAC significantly altered β-diversity (PERMANOVA, p < 0.05) and depleted primary fermenters in Muribaculaceae (-62%) and Bacteroidaceae (-77%) compared to the control group.”

    Animalshealthy rats; compared with the control groupgut22 mg/kg/day21 days

    Gut microbiota perturbation and systemic inflammation are associated with salcaprozate sodium (SNAC)-enabled oral semaglutide delivery

    Journal of controlled release : official journal of the Controlled Release Society

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 14 papers in 12 months